Sacubitril and Valsartan 97 mg + 103 mg: Uses, Benefits & Dosage
Sacubitril and Valsartan Tablets 97 mg + 103 mg are a prescription combination medicine used primarily as part of the treatment of certain patients with heart failure with reduced ejection fraction (HFrEF). SACUSMART 200, associated with Steris Healthcare, combines sacubitril and valsartan in a fixed-dose tablet.
This medicine belongs to a therapeutic approach known as angiotensin receptor-neprilysin inhibition (ARNI). Sacubitril and valsartan work through complementary pathways to reduce harmful neurohormonal effects on the cardiovascular system. Sacubitril increases the activity of beneficial natriuretic peptides by inhibiting neprilysin, while valsartan blocks the angiotensin II type-1 receptor.
The 97 mg + 103 mg strengths are commonly described together as a 200 mg total combination strength. The exact dose prescribed depends on the patient's medical condition, previous heart-failure treatment, kidney function, blood pressure, potassium level, age, and tolerability.
What Is Sacubitril and Valsartan Tablets 97 mg + 103 mg Used For?
Sacubitril and Valsartan Tablets 97 mg + 103 mg are used under medical supervision as part of treatment for appropriate patients with heart failure, particularly heart failure with reduced ejection fraction.
Heart failure occurs when the heart cannot pump blood efficiently enough to meet the body's requirements. Symptoms may include breathlessness, tiredness, reduced exercise tolerance, and swelling of the legs or feet.
Sacubitril/valsartan is designed to influence several mechanisms involved in heart failure, including vasoconstriction, sodium and water retention, and maladaptive cardiac remodeling.
Treatment should be individualized. The 97 mg + 103 mg strength may represent a target or higher maintenance strength for suitable patients after appropriate dose adjustment.
Why It's Important
Heart failure is a chronic condition requiring ongoing medical management. Treatment may include several approaches such as evidence-based medicines, lifestyle measures, monitoring, and management of underlying cardiovascular conditions.
Sacubitril/valsartan is important because it combines two mechanisms in one medicine. Rather than simply lowering blood pressure, its therapeutic role in appropriate heart-failure patients is to influence neurohormonal pathways involved in cardiovascular stress and disease progression.
Patients should take SACUSMART 200 exactly as prescribed and should not increase, decrease, or discontinue the medicine without consulting their healthcare professional.
Blood pressure, kidney function, and blood potassium may need to be monitored during treatment.
Key Benefits
When appropriately prescribed, potential therapeutic benefits include:
Helps reduce cardiovascular strain in appropriate heart-failure patients.
Combines neprilysin inhibition with angiotensin II receptor blockade.
Helps reduce vasoconstrictive activity.
Supports beneficial natriuretic peptide activity.
Can contribute to improved heart-failure management.
May reduce the risk of hospitalization for heart failure in appropriate patients.
May improve cardiovascular outcomes in selected patients with HFrEF.
What Are the Benefits of Sacubitril and Valsartan?
The major benefit of sacubitril and valsartan is its complementary mechanism of action.
Sacubitril helps increase the effects of natriuretic peptides, which can promote vasodilation and natriuresis and counter some harmful cardiovascular effects.
Valsartan blocks the AT1 receptor for angiotensin II. This reduces angiotensin-II-mediated vasoconstriction, sodium retention, and aldosterone-related effects.
Clinical evidence has demonstrated important benefits of sacubitril/valsartan in appropriately selected patients with heart failure with reduced ejection fraction compared with conventional ACE-inhibitor therapy in a landmark clinical trial.
However, individual results vary, and treatment decisions must be made by a qualified healthcare professional.
Side Effects
Like all prescription medicines, Sacubitril and Valsartan Tablets 97 mg + 103 mg can cause side effects.
Potential adverse effects include:
Low blood pressure.
Dizziness.
Headache.
Increased blood potassium.
Changes in kidney function.
Cough.
Fatigue.
Some patients may experience dizziness particularly when starting treatment or after a dose increase.
Patients should rise slowly from sitting or lying positions if they experience light-headedness.
Serious Side Effects
Serious reactions require prompt medical assessment.
Potential serious problems include:
Severe hypotension.
Significant deterioration in kidney function.
Hyperkalemia.
Severe allergic reaction.
Angioedema, including swelling of the face, lips, tongue, or throat.
Angioedema can be life-threatening if it affects the airway. Emergency medical assistance should be obtained if swelling of the tongue or throat or difficulty breathing develops.
Patients should also promptly report fainting, severe weakness, markedly reduced urination, or symptoms that may indicate a significant electrolyte or kidney problem.
Available Substitute
The appropriate substitute depends on the patient's diagnosis, ejection fraction, blood pressure, kidney function, potassium level, previous medicines, and treatment goals.
Potential alternative heart-failure therapies may include:
ARBs.
Evidence-based beta-blockers.
Mineralocorticoid receptor antagonists.
SGLT2 inhibitors.
Other guideline-directed heart-failure medicines.
However, these treatments are not direct substitutes in every patient.
An ACE inhibitor or ARB may be considered when sacubitril/valsartan cannot be used, but the decision should be made by the treating clinician.
Patients should not switch between heart-failure medicines independently.
Dosage Guidelines
The dosage of sacubitril/valsartan is individualized.
The 97 mg sacubitril + 103 mg valsartan combination is generally considered the higher commonly used twice-daily strength for adults who have been appropriately titrated and can tolerate it.
Treatment may begin at a lower strength in certain patients, followed by gradual dose adjustment.
Factors that may influence dosing include:
Previous ACE-inhibitor or ARB treatment.
Blood pressure.
Kidney function.
Potassium level.
Age.
Tolerability.
Severity of heart failure.
Other medicines being taken.
Do not change the dose of SACUSMART 200 without medical advice.
If a dose is missed, follow the instructions provided by the prescribing healthcare professional or current product information. Do not take an extra dose simply to compensate for a missed dose.
Precautions & Warnings
Sacubitril and Valsartan Tablets 97 mg + 103 mg require careful medical supervision because they can lower blood pressure and affect kidney function and serum potassium. The medicine must not be taken together with an ACE inhibitor because of the increased risk of angioedema; an appropriate washout period is required when switching between an ACE inhibitor and sacubitril/valsartan. Patients should tell their healthcare professional if they have previously experienced angioedema, significant kidney disease, liver disease, low blood pressure, or high potassium levels. Potassium supplements and potassium-containing salt substitutes should not be used routinely without medical advice. Certain medicines, including potassium-sparing diuretics, NSAIDs, lithium, and other medicines affecting the renin-angiotensin-aldosterone system, may require particular caution or monitoring. Blood pressure, kidney function, and potassium may be checked periodically. Pregnant patients should contact their healthcare professional immediately because medicines that act on the renin-angiotensin system can cause fetal harm.
Mechanism of Action
Sacubitril and valsartan work through complementary cardiovascular mechanisms.
Sacubitril is converted into its active metabolite, LBQ657, which inhibits the enzyme neprilysin. Neprilysin normally breaks down natriuretic peptides and several other vasoactive substances. By inhibiting neprilysin, sacubitril increases the activity of natriuretic peptide pathways, promoting effects such as vasodilation and sodium excretion.
Valsartan blocks the angiotensin II type-1 receptor. This inhibits the effects of angiotensin II mediated through AT1 receptors, including vasoconstriction, sodium retention, aldosterone-related effects, and other cardiovascular responses.
The mechanism can be summarized as:
Sacubitril → neprilysin inhibition → increased natriuretic peptide activity → vasodilation and natriuresis
Valsartan → AT1 receptor blockade → reduced angiotensin-II-mediated effects → reduced vasoconstriction and cardiovascular stress
Together, these mechanisms provide the pharmacological basis for sacubitril/valsartan therapy in appropriate patients with heart failure.
Clinical Evidence and Efficacy
Sacubitril/valsartan has been extensively studied in patients with heart failure with reduced ejection fraction.
The PARADIGM-HF trial compared sacubitril/valsartan with enalapril in patients with chronic HFrEF and found a significant reduction in the composite outcome of cardiovascular death or first hospitalization for heart failure with sacubitril/valsartan.
This evidence helped establish sacubitril/valsartan as an important component of guideline-directed therapy for suitable patients with HFrEF.
Importantly, clinical trial results apply to appropriately selected patient populations and should not be interpreted as a guarantee of individual outcomes.
Conclusion
Sacubitril and Valsartan Tablets 97 mg + 103 mg, marketed as SACUSMART 200 and associated with Steris Healthcare, are a fixed-dose ARNI combination used as part of evidence-based management for appropriate patients with heart failure, particularly heart failure with reduced ejection fraction.
Sacubitril inhibits neprilysin and enhances beneficial natriuretic peptide activity, while valsartan blocks AT1 receptors and reduces the effects of angiotensin II. Their complementary mechanisms help address important neurohormonal pathways involved in heart failure.
Because this medicine can affect blood pressure, kidney function, and potassium levels, treatment requires appropriate medical supervision. Patients should not change the dose, discontinue therapy, or substitute another heart-failure medicine without professional guidance.
For pharmaceutical procurement, pharmacies, hospitals, distributors, and institutional buyers, the exact composition, strength, pack information, storage requirements, batch details, expiry date, regulatory documentation, and current product specifications should be verified before purchase or supply.
Comments
Post a Comment